NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
Seagen Inc.
Astellas Pharma Inc
Astellas Pharma Inc
Hoffmann-La Roche
AstraZeneca
National Cancer Institute (NCI)